Veracyte increases revenue to $92M, in turn sees 26% improvement in net loss 2018

Veracyte delivered growth in 2018 and are off to a strong start in 2019, as it posted $92.0 million revenue for full year, an increase of 28%, with net loss of $23.0 million, an improvement 26%.

Bonnie Anderson, Veracyte’s chairman and chief executive officer says: “Our 2018 performance was driven by several factors. Our Afirma GSC and Xpression Atlas launch broadened our thyroid offering to inform both diagnosis and treatment decisions, and the first full year of Percepta classifier adoption was strong with the fourth quarter acceleration in growth positioning us for a strong 2019. Clearly, our multi-product sales strategy that is designed to give us the leverage we need to be a profitable enterprise is working.”

The company entered into biopharmaceutical collaborations with Loxo Oncology and Johnson & Johnson Innovation and the Johnson & Johnson Lung Cancer Initiative in 2018.